Seoyeon Oh

Immune checkpoint inhibitors (ICIs) have revolutionized as one of the pillars of cancer treatment, which are a type of immunotherapy that kills cancer cells by blocking immune checkpoint proteins. While there is an increase in the number of treated cancer patients via ICIs, minimally invasive response prediction tests are still difficult and expensive. The development of single-cell technologies has accelerated research in oncology by identifying heterogeneous cell (sub-)populations based on the epigenetic layers of information. In my project, I aim to give better insights of the systemic immunity associated with ICI therapy response, involved in NIPIT project (Non-Invasive Prediction of Immunotherapy Response). To achieve this goal, I analyze in-house single-cell sequencing data as well as bulk sequencing data of cancer patients’ blood. I believe that inferring the response-specific gene regulatory networks based on integrative single-cell multi-omics analysis will aid in the identification of accurate predictive biomarkers for the response. 
 

• Lab address: CMB building, Technologiepark, Zwijnaarde 75, 9052 Gent, Belgium
• TOBI Lab
• Center for Medical Biotechnology
• Department of Biomolecular Medicine UGent
• LinkedIn
• Seoyeon Oh is interested to receive invitations for presentations or talks